RevitalVision's break through technology is the only clinically proven and FDA approved therapy with efficacy claim for improving vision in adult amblyopia, effecting 2%-5% of the world population. Amblyopia is the number 1 cause for impaired vision from infancy until the age of 40 and is considered untreatable after the age of 9.
The technology is also effective in improving vision in a number of other visual impairments and conditions. RevitalVision provides additional significant vision improvement beyond what is currently available by only treating the eyes. The average vision improvement is 2.5 lines on the visual acuity chart, and 100% in contrast sensitivity (about 20% - 25% vision improvement). Most amblyopic patients also improve stereo acuity and binocular function.
Our team comprises of medical experts and multi-disciplinary professionals that together address the need of hundreds of millions of people worldwide suffering from different visual impairments and who, until now, had no effective alternative solution to improve their condition.